Alexey Filippov

Dr. Alexey Filippov


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
OAOnno W. Akkerman
Onno W. Akkerman
AAAlena Aleksa
Alena Aleksa
JAJan-Willem C Alffenaar
Jan-Willem C Alffenaar
NANada Hassan Al-Marzouqi
Nada Hassan Al-Marzouqi
MAMiguel Arias-Guillén
Miguel Arias-Guillén
MZMatteo Zignol
Matteo Zignol
The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile. A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019.

1 January 2019 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
SBS. E. Borisov
S. E. Borisov
AFAlexey Filippov
Alexey Filippov
DID. А. Ivаnovа
D. А. Ivаnovа
TIT. N. Ivаnushkinа
T. N. Ivаnushkinа
NLN. V. Litvinovа
N. V. Litvinovа
YGYu. Yu. Gаrmаsh
Yu. Yu. Gаrmаsh
Цель: определить эффективность и безопасность режимов химиотерапии, включающих бедаквилин, у больных туберкулезом органов дыхания в условиях повседневной клинической практики при минимальных критериях невключения пациентов. Материалы и методы. В проспективном открытом нерандомизированном одноцентровом исследовании у 315 больных изучены эффективность и безопасность режимов химиотерапии туберкулеза, основанных на первоочередном назначении бедаквилина, линезолида, левофлоксацина/моксифлоксацина и циклосерина/теризидона. Длительность наблюдения за пациентами составила не менее 24 мес., широкая лекарственная устойчивость микобактерий туберкулеза (МБТ) имела место у 52,4%, большинство пациентов (50,8%) имело неэффективный предыдущий курс лечения, серьезная сопутствующая патология выявлена у 89,5% пациентов. Результаты исследования. У 104 пациентов длительность приема бедаквилина была ограничена стандартными 24 нед., у 42 – продлена до 36 нед., у 56 – до 48 нед., а 94 пациента получали бедаквилин более 48 нед. Увеличение длительности приема бедаквилина свыше 24 нед. обеспечило достоверное повышение эффективности лечения (вне зависимости от спектра лекарственной устойчивости МБТ) с 66,2% (95%-ный ДИ 54,4-77,9%) до 84,3% (95%-ный ДИ 80,0-89,7%). Отмечена хорошая переносимость используемых режимов: серьезные нежелательные побочные реакции (НПР) отмечены только у 27,6% пациентов, причем вклад бедаквилина в их развитие не является существенным (отмена бедаквилина из-за НПР потребовалась в 2,2% случаев). Спектр НПР практически не отличается от такового при использовании только традиционных противотуберкулезных препаратов.

12 February 2020 in Tuberculosis and Lung Diseases
Verified
Journal Article
Open access
PDF file
DID. A. Ivanova
D. A. Ivanova
SBS. E. Borisov
S. E. Borisov
ORO. V. Rodina
O. V. Rodina
AFAlexey Filippov
Alexey Filippov
TIT. N. Ivanushkina
T. N. Ivanushkina
NLN. V. Litvinova
N. V. Litvinova
The objective: safety assessment of chemotherapy regimens compiled in accordance with the recommendations of World Health Organization (WHO), 2019, in patients with multiple drug resistant tuberculosis (MDR) in clinical practice settings.Subjects: Frequency, patterns, severity and risk factors of adverse events (AE) of chemotherapy regimens compiled in accordance with the WHO recommendations as of 2019 were analyzed in 122 patients with MDR and XDR respiratory tuberculosis within programmatic use of new anti-tuberculosis drugs.Results. The frequency of AE made 64.8% (95% CI 55.9-72.7%), gastrointestinal, cardiovascular and allergic events prevailed, the comorbidity was the risk factor of AE development (OR 6.44; 95% CI 1.91-21.76). AEs of with severity degrees 3-4 were observed in 24.6% (95% CI 17.8-33.0%), neurotoxic, ototoxic and hepatotoxic reactions prevailed; risk factors included female sex (OR 3.15, 95% CI 1.32-7.53) and complications of chemotherapy in the past (OR 3.50%, 95% CI 1.49-8.70). At least one anti-tuberculosis drug was canceled due to AE in 26.2% (95% CI 19.2-34.7%), and any of Group A drugs was canceled during the first 6 months of chemotherapy in 13.9% (95% CI 8.8-21.3%) of patients.

13 October 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
AUAnastasia Ushtanit
Anastasia Ushtanit
YMYulia Mikhailova
Yulia Mikhailova
ALAlexandra Lyubimova
Alexandra Lyubimova
MMMarina Makarova
Marina Makarova
SSSvetlana Safonova
Svetlana Safonova
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
Background: Linezolid, bedaquiline, and newer fluoroquinolones are currently placed as priority Group A drugs for the treatment of drug-resistant tuberculosis. The number of reported linezolid-resistant clinical strains is still low, and the correlation of molecular determinants with phenotype is not perfect. Methods: We determined the linezolid MICs for clinical isolates from the Moscow region and identified mutations in rplC and rrl genes. Results: All 16 linezolid-resistant isolates had previously reported mutations in the rplC or rrl loci, and 13 of them bore a RplC C154R substitution. Detection of this substitution in a heteroresistant state was not successful, probably, due to the more stable DNA secondary structure of the mutated fragment, which precludes its amplification in mixes with the wild-type DNA. Strains with an rplC mutation had higher linezolid MIC compared to isolates with rrl mutations. Conclusions: Linezolid resistance mostly emerged during treatment with the latest regimen. Three primary cases with linezolid resistance question the possible transmission of totally drug-resistant tuberculosis in the Moscow region, which demands further investigation.

Verified
Journal Article
Open access
PDF file
AUAnastasia Ushtanit
Anastasia Ushtanit
IPIrina Peretokina
Irina Peretokina
LKLudmila Krylova
Ludmila Krylova
SSSvetlana Safonova
Svetlana Safonova
AFAlexey Filippov
Alexey Filippov
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
Tuberculosis is one of the hardest-to-treat bacterial diseases with a high capacity to develop antibiotic resistance. The treatment scheme based on bedaquiline and linezolid was introduced in Russia in 2014 and, since 2018, has been widely used for the treatment of resistant tuberculosis. In our study of clinical M. tuberculosis isolates, we identified a case of a recent transmission of a strain with mutations in the genes rv0678 and rplC, associated with resistance to bedaquiline and linezolid. We analyzed five isolates obtained from patient A between 2015 and 2019 after unsuccessful treatment and three isolates from patient B obtained between diagnosis in 2019 and death in mid-2020 via whole-genome sequencing and 24-loci MIRU-VNTR genotyping. During the treatment of patient A, a large spectrum of different mutations in rv0678 developed, accompanied by an increase in bedaquiline MIC from 0.06 to 0.5 mg/L. Simultaneously, rplC C154R substitution emerged, leading to linezolid resistance. The isolates from patient B contained nearly the same mutation spectra as the isolates from patient A, differing in only four variants that emerged during transmission. The possible transmission event must have occurred in a public place in Moscow, since there was no evidence of direct contact between the patients. This finding confirms the worrying trend of untreatable M. tuberculosis strains circulating in the general population.